Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients.
Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K, Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T. Maeda M, et al. Among authors: takaki s. Liver Cancer. 2020 Jan;9(1):50-62. doi: 10.1159/000502744. Epub 2019 Oct 22. Liver Cancer. 2020. PMID: 32071909 Free PMC article.
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong S, et al. Among authors: takaki s. World J Gastroenterol. 2007 Oct 21;13(39):5188-95. doi: 10.3748/wjg.v13.i39.5188. World J Gastroenterol. 2007. PMID: 17876889 Free PMC article. Clinical Trial.
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong SC, et al. Among authors: takaki s. World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K. Uka K, et al. Among authors: takaki s. Liver Int. 2007 Nov;27(9):1209-16. doi: 10.1111/j.1478-3231.2007.01554.x. Liver Int. 2007. PMID: 17919232
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. Takaki S, et al. Intervirology. 2007;50(6):439-46. doi: 10.1159/000114718. Epub 2008 Feb 4. Intervirology. 2007. PMID: 18253048 Clinical Trial.
Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H, Waki K, Imamura M, Aikata H, Takahashi S, Chayama K. Jeong S, et al. Among authors: takaki s. J Gastroenterol Hepatol. 2008 Apr;23(4):541-5. doi: 10.1111/j.1440-1746.2008.05356.x. J Gastroenterol Hepatol. 2008. PMID: 18397484 Clinical Trial.
333 results